Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Organon & Co. is a healthcare company focused on women's health and other critical health issues....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth provides insight into the company's ability to expand its market share and product offerings.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Organon & Co. is a healthcare company focused on women's health and other critical health issues. With a market cap of $4 billion, it plays a vital role in the pharmaceutical industry, addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1-2026, Organon reported an EPS of $0.71, missing expectations by 12.88%. The stock reacted negatively, declining 0.67% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Organon's upcoming earnings are mixed, with no analyst estimates available. The market is uncertain about the company's growth trajectory.

Bull Case

If Organon can demonstrate strong revenue growth and improve its EPS, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear growth strategy, it could face further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, a strong EPS could signal recovery, while another miss could further erode investor confidence.

How is revenue growth trending in key segments?

Understanding revenue trends will help gauge the company's market position and potential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS given recent product launches and market expansion efforts.

Supporting Evidence

Organon's recent product pipeline indicates potential for improved revenue streams.

Historical trends show that the company has a 75% EPS beat rate, suggesting a likelihood of positive surprises.

The options market's implied volatility suggests that investors are bracing for significant news, which could lead to a positive outcome.

Key Risk

If the EPS exceeds $0.85, it could challenge the consensus view and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial for determining whether Organon can stabilize its financials and regain market trust.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate a positive turnaround.

Bear Confirmed If

An EPS below $0.65 would likely confirm the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise around 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may remain volatile as investors digest the commentary.

Miss

If the company misses again, history indicates a potential decline of about 4.43%, raising concerns about its growth strategy.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product launches and their impact on revenue.
2Management's outlook on market conditions and competition.
3Any changes to guidance for the remainder of the fiscal year.
4Insights into cost management and operational efficiency.
5Details on strategic partnerships or acquisitions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Organon & Co. is a healthcare company focused on women's health and other critical health issues....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth provides insight into the company's ability to expand its market share and product offerings.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1-2026, Organon reported an EPS of $0.71, missing expectations by 12.88%. The stock reacted negatively, declining 0.67% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Organon's upcoming earnings are mixed, with no analyst estimates available. The market is uncertain about the company's growth trajectory.

Bull Case

If Organon can demonstrate strong revenue growth and improve its EPS, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear growth strategy, it could face further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent performance, a strong EPS could signal recovery, while another miss could further erode investor confidence.

How is revenue growth trending in key segments?

Understanding revenue trends will help gauge the company's market position and potential for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS given recent product launches and market expansion efforts.

Supporting Evidence

Organon's recent product pipeline indicates potential for improved revenue streams.

Historical trends show that the company has a 75% EPS beat rate, suggesting a likelihood of positive surprises.

The options market's implied volatility suggests that investors are bracing for significant news, which could lead to a positive outcome.

Key Risk

If the EPS exceeds $0.85, it could challenge the consensus view and shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial for determining whether Organon can stabilize its financials and regain market trust.

Bull Confirmed If

An EPS of $0.85 or higher would confirm the bull case and indicate a positive turnaround.

Bear Confirmed If

An EPS below $0.65 would likely confirm the bear case, suggesting ongoing struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could rise around 3.1%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may remain volatile as investors digest the commentary.

Miss

If the company misses again, history indicates a potential decline of about 4.43%, raising concerns about its growth strategy.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product launches and their impact on revenue.
2Management's outlook on market conditions and competition.
3Any changes to guidance for the remainder of the fiscal year.
4Insights into cost management and operational efficiency.
5Details on strategic partnerships or acquisitions.